Spinal Cord Injury Clinical Trials Review: A Multitude of Emerging Drugs for Better Treatment
Phase III and is being developed by Kringle Pharma. HGF was given an orphan drug designation for Acute Spinal Cord Injury by the Japanese Ministry of Health, Labour and Welfare in September 2019. In October 2019, GTX Medical and NeuroRecovery Technologies announced their merger to create a leading global company committed to developing novel neuromodulation therapies to improve people’s functional recovery with Spinal Cord Injuries. The merged entity will be known as GTX Medical BV. The merged company is developing Targeted Epidural Spine Stimulation (TESS), an implantable spinal cor...
Source: globenewswire.com